Navigation Links
Final Results of Boceprevir Phase II HCV SPRINT-1 Study Showed Significantly Higher SVR Rates Compared to Standard of Care in Treatment-Naive Genotype 1 Hepatitis C Patients
Date:4/23/2009

3 through 17 years receiving PEGINTRON/REBETOL combination therapy, weight loss and growth inhibition were common.

Patients receiving PEGINTRON and REBETOL as retreatment after failing a previous interferon combination regimen reported adverse reactions similar to those previously associated with this regimen during clinical trials of treatment-naive patients.

Please see important full U.S. prescribing information and the Medication Guide for PEGINTRON at www.schering-plough.com.

About Schering-Plough

Schering-Plough is an innovation-driven, science-centered global health care company. Through its own biopharmaceutical research and collaborations with partners, Schering-Plough creates therapies that help save and improve lives around the world. The company applies its research-and-development platform to human prescription, animal health and consumer health care products. Schering-Plough's vision is to "Earn Trust, Every Day" with the doctors, patients, customers and other stakeholders served by its colleagues around the world. The company is based in Kenilworth, N.J., and its Web site is www.schering-plough.com.

SCHERING-PLOUGH DISCLOSURE NOTICE: The information in this press release includes certain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including statements relating to the potential market for PEGINTRON and REBETOL. Forward-looking statements relate to expectations or forecasts of future events. Schering-Plough does not assume the obligation to update any forward-looking statement. Many factors could cause actual results to differ materially from Schering-Plough's forward-looking statements, including uncertainties in the regulatory process, among other uncertainties. For further details
'/>"/>

SOURCE Schering-Plough Corporation
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related medicine technology :

1. Aegerion Pharmaceuticals, Inc. Presents Final Results of Phase II Clinical Trials for AEGR-733 at Drugs Affecting Lipid Metabolism (DALM) 2007 Conference
2. Daiichi Sankyo and Forest Laboratories Finalize Contract for Co-Promotion of AZOR(TM)
3. Oral Talactoferrin Alfa Improves Overall Survival in Patients With Refractory Non-Small Cell Lung Cancer: Final Phase 2 Study Results Presented at the 8th Annual Targeted Therapies for the Treatment Of Lung Cancer Meeting
4. Nventa Enrolls and Initiates Dosing of Final Cohort in HspE7 Phase 1 Cervical Dysplasia Trial
5. Final Data From the SEISMIC Trial Suggest Safety, Efficacy of Autologous Stem- Cell Therapy for Treating Congestive Heart Failure
6. Final Data From the Bioheart Seismic Trial Suggest Safety, Efficacy of Autologous Stem-Cell Therapy for Treating Congestive Heart Failure
7. Poniard Pharmaceuticals Announces Final Picoplatin Data from Phase 2 Small Cell Lung Cancer Trial Demonstrating Survival Benefit
8. Nventa Completes Safety Evaluation on Final Cohort in HspE7 Phase 1 Cervical Dysplasia Trial
9. Final Results of Ideal Study Presented at Annual Meeting of the European Association for the Study of the Liver (EASL)
10. The Anatomy of Clinical Trials: Greys Season Finale Leaves Public in the Dark About the Myths and Realities
11. Final Results of the CellCept(R) Spare the Nephron (STN) Study Show Maintenance Therapy is Associated with Improved Renal Function
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2014)... McGraw-Hill Education Professional, a leading global provider ... medical communities, has announced the launch of the ... the world-renowned medical education platform. A ... available for download onto all iOS and Android devices, ... access to valuable AccessMedicine diagnostic resources in ...
(Date:7/29/2014)... -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX ) announced ... 2014 financial results after the Nasdaq market closes on ... live conference call and webcast to discuss its financial ... 7, 2014 at 8:00 a.m. Eastern Time (5:00 a.m. ... conference call by dialing 866-952-1907 (US) or 785-424-1826 (International) ...
(Date:7/29/2014)... July 29, 2014 Research and Markets ... Respiratory Devices Market 2014-2018" report to their offering. ... A respiratory device is a medical device used to ... difficulty in breathing and cannot achieve adequate oxygen levels ... cystic fibrosis, asthma, COPD, and ARDS require the need ...
Breaking Medicine Technology:McGraw-Hill Education Professional's AccessMedicine App Delivers Instant Access to Essential Diagnostic Tools 2McGraw-Hill Education Professional's AccessMedicine App Delivers Instant Access to Essential Diagnostic Tools 3Neurocrine Biosciences Announces Conference Call And Webcast To Report Second Quarter 2014 Financial Results 2Global Respiratory Devices Market 2014-2018 2
(Date:7/29/2014)... MO (PRWEB) July 30, 2014 ... have recently been awarded the Patient-Centered Medical Home ... the National Committee for Quality Assurance. Only one ... NCQA Level I, Level 2, or Level 3 ... participate in Patient-Centered Medical Home report faster access ...
(Date:7/29/2014)... St. Petersburg, FL (PRWEB) July 30, 2014 Phytceramides ... explains how and why in her new book. , Today is ... Phytoceramides: Anti Aging At Its Best . The book is ... larger skin care book, but felt that Phytoceramides were ... sense to bring out this focused book now," says Kathy Heshelow, ...
(Date:7/29/2014)... (PRWEB) July 29, 2014 1Heart ... senior communities with focus on Brain Fitness Education ... in Ventura. Brain Fitness Program Director Tee Barr ... Aegis Memory Care unit and the Assisted Living ... Aegis Life Enrichment Director Christy Rozsa and Aegis ...
(Date:7/29/2014)... Ireland (PRWEB) July 30, 2014 Dignity ... the successful completion of a Phase I trial with ... (DGLA). , This study was a randomized, placebo-controlled, double-blind, ... assess the safety, pharmacokinetics and effect of food on ... the benign safety profile of DGLA following both single ...
(Date:7/29/2014)... VogueQueen.com, a well-known online supplier, now allows worldwide ... garment fashion by providing graceful and sexy lingerie collection ... array of sexy dresses , designed and developed ... customers take price into consideration. Worry no more, because ... more affordable for all clients. , VogueQueen.com’s top ...
Breaking Medicine News(10 mins):Health News:Saint Luke’s Medical Group Awarded Patient-Centered Medical Home 2011 Level 3 Recognition 2Health News:Last Day New Book Is Available at No Cost: Phytoceramides, Anti Aging At Its Best by Sublime Beauty Founder® Kathy Heshelow 2Health News:Last Day New Book Is Available at No Cost: Phytoceramides, Anti Aging At Its Best by Sublime Beauty Founder® Kathy Heshelow 3Health News:1Heart Caregiver Services Conducts Brain Fitness Education and Brings Tee Barr to Aegis Ventura 2Health News:1Heart Caregiver Services Conducts Brain Fitness Education and Brings Tee Barr to Aegis Ventura 3Health News:1Heart Caregiver Services Conducts Brain Fitness Education and Brings Tee Barr to Aegis Ventura 4Health News:DS107G-01 – Successful Completion of Phase I Oral DGLA Clinical Trial 2Health News:VogueQueen.com Now Provides Graceful And Sexy Lingerie Collection For August 2
... Jan. 3 (HealthDay News) -- Parents can involve their children ... the works, says one fitness expert, by making exercise seem ... take the kids out for a walk this evening, most ... the video games or television?," cautioned Michael Berry, chair of ...
... diagnosed with schizophrenia and other psychoses appear to show ... cerebrospinal fluid in the frontal lobe compared to healthy ... report in the January issue of Archives of ... "Progressive loss of brain gray matter (GM) has been ...
... from visceral fat called adiponectin may play a role as ... disease (AD) in women, according to a study published Online ... the JAMA/Archives journals. The number of people affected by ... years from the current number of about 36 million people, ...
... HealthDay Reporter , MONDAY, Jan. 2 (HealthDay ... leaves people feeling good about themselves and positive about ... mean practicing random acts of kindness has scientifically proven ... Yes, according to a growing body of research that ...
... FRIDAY, Dec. 30 (HealthDay News) -- Researchers have identified ... for developing the thyroid cancer, with one in particular ... for the disease. Dr. Charis Eng, founding director ... Research Institute, said in a news release that her ...
... News) --,Overcrowding in emergency rooms appears to keep children ... in a timely manner, according to a new study. ... Medicine said their findings are significant since these injuries, ... and very painful. "Pain associated with long bone ...
Cached Medicine News:Health News:Fun Ways to Include Kids in Fitness Resolutions 2Health News:Schizophrenia diagnosis associated with progressive brain changes among adolescents 2Health News:Study finds another potential risk factor for developing dementia and Alzheimer's disease in women 2Health News:With Depression, Helping Others May in Turn Help You 2Health News:With Depression, Helping Others May in Turn Help You 3Health News:Gene Mutations Linked to Thyroid Cancer Risk: Study 2Health News:Crowding in ER May Delay Pain Relief for Kids 2
... dedicated fluorometer from Berthold Technologies, has ... variety of measurement modes to support ... scanning, dual ratio measurements plus top ... valuable instrument for any researcher using ...
The VICTOR² D fluorometer is suitable for clinical assays based on fluorescence or time-resolved fluorescence from a wide variety of plates....
... VISUCAM non-mydriatic fundus camera ... simplicity of fundus imaging. ... to set the standard ... features a unique combination ...
Small, compact and versatile, the CLK-4 light source is compatible with all Olympus fiberscopes and is ideal for the vast majority of routine fiber-endoscopic procedures, especially in the out-patien...
Medicine Products: